Opioid Addiction Treatments That May Surface in 2018

Is a ‘smarter’ opioid on the way?

A study published today in the journal Cell concludes that it’s possible to create pain-relieving opioids that don’t cause side effects. These side effects include anxiety, nausea, and dependency.

As they are, opioids bind to receptors on the cell surface.

A team led by researchers at the University of North Carolina School of Medicine examined how the kappa opioid receptor (KOR), a protein on the cell surface, is activated.

With that knowledge, the researchers say they developed a new drug-like compound that only activates that receptor.

That way, the opioids only relieve pain and aren’t addictive.

Knowing that structure, Dr. Bryan Roth, a professor at UNC-Chapel Hill, said that drug-like compounds could be developed to be more selective to specific opioid receptors.

By targeting KORs, the few drugs that bind to it don’t lead to addiction or cause death due to overdose, Roth explained.

“Drugs targeting this receptor are likely to have low-addiction potential and to not be associated with respiratory depression, which leads to death in opioid overdoses,” Roth told Healthline.

In addition, Amber C. Lindsey, LCDC-I, a program director at Taylor Recovery Center in Houston, told Healthline that vaccines are currently being developed to target opioids in the bloodstream in hopes of preventing the drug from reaching the brain and exerting euphoric effects.

Additionally, work is being done to explore the potential use of transcranial direct current stimulation, a noninvasive brain stimulation technique for treating opioid use disorder.

Treating addiction with other drugs

While 12-step programs can work effectively to treat alcohol use disorder, that’s not the case for people addicted to opioids.

Remedying opioid addiction with medication-assisted treatment is the most promising avenue, says Andrew Kolodny, co-director of the Opioid Policy Research Collaborative at Brandeis University in Massachusetts.

First, he notes, the country must prevent people from becoming addicted. That requires being more cautious in prescribing opioids.

“Prescribing practices have to change,” Kolodny told Healthline.

Second, it may be necessary to treat people who are already addicted with other drugs.

The country as a whole, Kolodny said, isn’t making it easy to access these addiction-defeating drugs.

Buprenorphine remains the best treatment for opioid addiction. It’ll soon be available as a monthly injection so people don’t have to remember to take a pill daily.

However, Kolodny noted that although doctors can prescribe opioids, they’re more regulated when prescribing the treatment for opioid addiction.

Physicians must complete an eight-hour training to apply for permission to prescribe buprenorphine under The Drug Addiction Treatment Act of 2000.

The law grants a Drug Enforcement Agency (DEA) waiver to doctors who complete training to prescribe buprenorphine to treat opioid use disorder. There are limits on the numbers of patients a doctor can treat, though.

Most of the doctors doing this don’t take insurance, so funding the treatment has to come out of pocket.

Another challenge to getting treatment is that many people with an opioid addiction don’t know that buprenorphine is an effective treatment, Kolodny said.

Along with buprenorphine, other FDA-approved options for treating opioid addiction include methadone and naltrexone.

They’ve been tested extensively for effectiveness and safety, said Dr. Edwin A. Salsitz, an addiction medicine specialist at Mount Sinai Beth Israel in New York City.

“Generally the medications are combined with psychosocial treatments to provide the optimal outcomes,” Salsitz told Healthline.

Methadone maintenance is helpful for people who don’t do well with buprenorphine. But people have to visit a clinic daily to receive that treatment.

Suboxone is another viable treatment akin to buprenorphine, Kolodny added.

Another barrier to treatment is giving people geographical access to assistance.

A study in Annals of Family Medicine found that about 60 percent of rural counties in the United States don’t have a doctor that can prescribe buprenorphine.

When people hear about drugs for opioid treatment, they may think of the nasal spray Narcan.

While it’s more readily available, people saved by the Narcan antidote may simply overdose again.

“It’s too downstream an intervention,” Kolodny said. “If you save someone and you don’t treat them, you’re just going to have to treat them with it again.”

The Regulation Route

Kolodny says doctors must be regulated and trained in prescribing opioids.

In addition, restrictions that limit buprenorphine access must be lifted.

Manufacturers must also be regulated, Kolodny added.

“The reason we have this epidemic is because doctors started to prescribe aggressively in response to a deceptive marketing campaign that didn’t talk about addiction,” Kolodny said.

The Pharmaceutical Research and Manufacturers of America (PhRMA), in partnership with the Addiction Policy Forum, recently launched “Priorities to Address Addiction in America,” an initiative to address the opioid crisis.

The plan attempts to pinpoint gaps in existing programs, boost education, and connect people to treatment, among other actions.

The organization is also proposing policies that limit the supply of opioid medications to seven days for acute pain, mandate prescriber training, and eliminate coverage barriers that keep patients from accessing all forms of addiction treatment.

A Multifaceted Approach

Salsitz believes there are several methods that can be employed to ease the opioid crisis.

Among them are wider Narcan distribution, more funding for prevention and treatment, decreasing the importation of fentanyl into the United States, and decreasing societal issues that result in increased vulnerability to opioid addiction.

“There is no silver-bullet solution to the opioid epidemic,” Salsitz said. “A multipronged, multidimensional effort is required. Effective treatment exists. Greater accessibility is required.”

Mark W. Parrino, MPA, president of the American Association for the Treatment of Opioid Dependence (AATOD), told Healthline that it’ll be some time before Americans break free from opioid addiction.

He noted that the criminal justice system has been slow to provide treatment access — something that is changing slowly.

Nevada is one of more than a dozen states that have regulations in place to limit the number of days for an opioid prescription or limit its strength.

A new program there has installed pre-prescription safeguards for doctors. It also bolsters the requirements to continue a prescription after one month, three months, and a year.

Visit the aatod conference website for more details…www.aatodconference.com.

@aatod1984
  • 3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone.

Register ➡️ bit.ly/3Vz1RPE
  • Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 

On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. 

In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  

REGISTER ➡ https://conta.cc/3TF9CSQ

View the final rule ➡ https://lnkd.in/e_iu-AtG.

There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. 

We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. 

This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW
(Director - CSAT’s Division of Pharmacologic Therapies).

The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
  • Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024

The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment.

To become an exhibitor today —> https://bit.ly/48ZKMRX
  • TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION

💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w,
for the most up-to-date details regarding the upcoming #aatod2024 Conference -
The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD 

Registration ➡️ www.aatodconference.com
  • TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024

TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD.

For registration and hotel information ➡️ bit.ly/3Ue57Q6.

We look forward to seeing you in Las Vegas!
  • #aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6.

The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment.

The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders.  We hope to see you in Las Vegas!
  • Patient access to OTPs saves lives every day.

AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. 

Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
  • Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. 

“Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA 

Read More ➡️ bit.ly/3tKb1gy
  • Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
  • Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. 

Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. 

Register ➡️ bit.ly/461CkkG
3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone.

Register ➡️ bit.ly/3Vz1RPE
3/28 Expanding Access to #Methadone in Correctional Facilities will focus on opportunities to expand access to methadone in correctional facilities, including recent developments with the SAMHSA 2024 final rule on the use of methadone. Register ➡️ bit.ly/3Vz1RPE
2 days ago
View on Instagram |
1/10
Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 

On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. 

In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  

REGISTER ➡ https://conta.cc/3TF9CSQ

View the final rule ➡ https://lnkd.in/e_iu-AtG.

There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. 

We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. 

This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW
(Director - CSAT’s Division of Pharmacologic Therapies).

The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
Invitation to SAMHSA Webinars on 42 CFR Part 8 💻 On February 2, 2024, the final rule for 42 CFR Part 8 was published. The effective date for these regulations is April 2, 2024, with an implementation date of October 2, 2024. In preparation for implementation of the revisions, SAMHSA will provide two preliminary webinars for OTPs.  The first will focus on administrative areas; the second will focus more on clinical content. These will be held on March 20th (from 2-3pm EST) and March 27th, 2024 (from 2- 3pm EST).  REGISTER ➡ https://conta.cc/3TF9CSQ View the final rule ➡ https://lnkd.in/e_iu-AtG. There will be an opportunity to receive an overview of the rule changes and discuss with SAMHSA the implications of the changes. We encourage you to attend these important meetings to assist you in determining how you will need to prepare for full implementation of these regulations. This webinar series will be moderated by Mark W. Parrino, MPA (AATOD President). Speakers include Yngvild Olsen, MD, MPH (Director - CSAT), Robert Baillieu, MD, MPH, FAAFP (Physician and Senior Advisor - SAMHSA/CSAT, and Patti Juliana, PhD, LCSW (Director - CSAT’s Division of Pharmacologic Therapies). The presentations will be followed by Q&A, and these webinars will become available to the public for On-Demand viewing via the AATOD website. Certificates of Attendance will be provided per request.
1 week ago
View on Instagram |
2/10
Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024

The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment.

To become an exhibitor today —> https://bit.ly/48ZKMRX
Don’t miss out on the chance to show your support, share your products/services and secure your sponsorship at the AATOD 2024 Conference, �The world’s premier training conference event for the Treatment of Opioid Use Disorder. #aatod2024 The 2024 AATOD Conference will attract over 1,600 physicians, social workers, nurses, counselors, program administrators, executive directors, and other treatment providers from many countries. The registrants are decision-makers with purchasing power for their treatment centers and are looking for new products, services, and information to improve their patient treatment. To become an exhibitor today —> https://bit.ly/48ZKMRX
2 weeks ago
View on Instagram |
3/10
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION

💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w,
for the most up-to-date details regarding the upcoming #aatod2024 Conference -
The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD 

Registration ➡️ www.aatodconference.com
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION 💻 View the latest Conference Video Message from AATOD's President, Mark W. Parrino bit.ly/48y815w, for the most up-to-date details regarding the upcoming #aatod2024 Conference - The world's premier training conference event for the treatment of Opioid Use Disorder. #OUD Registration ➡️ www.aatodconference.com
1 month ago
View on Instagram |
4/10
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024

TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD.

For registration and hotel information ➡️ bit.ly/3Ue57Q6.

We look forward to seeing you in Las Vegas!
TREATING OPIOID USE DISORDER: SO MUCH MORE THAN MEDICATION #aatod2024 TODAY is the last day to take advantage of the discounted registration rate. #aatod2024 is the world’s premier training conference event for the treatment of #OUD. For registration and hotel information ➡️ bit.ly/3Ue57Q6. We look forward to seeing you in Las Vegas!
2 months ago
View on Instagram |
5/10
#aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6.

The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment.

The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders.  We hope to see you in Las Vegas!
#aatod2024 Conference Update. Comprehensive Listing/Descriptions of Workshops, Posters, and Hot Topic Roundtable Conference Sessions are now available ➡️ http://bit.ly/3Ue57Q6. The workshop committee is pleased to present a dynamic workshop lineup that includes extremely rich and diverse educational content for all disciplines. You will hear from experts who will share the latest research and developments relating to opioid use disorders and treatment. The workshop lineup will include state of the art information on diverse areas of focus such as patient care and best practices, building community partnerships and collaborations, public policy and regulatory changes, workforce development, quality assurance, and financial reimbursement. There will be workshops that focus on emerging treatment trends and developments such as the fentanyl epidemic, mobile opioid treatment programs, regulatory changes, expansion of treatment services in rural areas, integrating treatment with the corrections systems, and integrating harm reduction initiatives. For those newer to the field or those who want a refresher on the basics, we have once again included a “Foundations” track which will include selections on the fundamentals of medication assisted treatment. The conference will continue to be the world’s premier training and education event for the treatment of opioid use disorders. We hope to see you in Las Vegas!
2 months ago
View on Instagram |
6/10
Patient access to OTPs saves lives every day.

AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. 

Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
Patient access to OTPs saves lives every day. AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
4 months ago
View on Instagram |
7/10
Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. 

“Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA 

Read More ➡️ bit.ly/3tKb1gy
Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. “Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA Read More ➡️ bit.ly/3tKb1gy
5 months ago
View on Instagram |
8/10
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery. Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1 For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
6 months ago
View on Instagram |
9/10
Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. 

Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. 

Register ➡️ bit.ly/461CkkG
Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. Register ➡️ bit.ly/461CkkG
6 months ago
View on Instagram |
10/10

Invitation to SAMHSA Webinars on 42 CFR Part 8 💻
In preparation for implementation of the revisions, #SAMHSA will provide two preliminary #webinars for #OTPs - administrative areas & clinical content. Register ➡️ https://conta.cc/3TF9CSQ.

Load More...

#aatod2024 Conference – Las Vegas

COUNTDOWN

2024 Conference

AATOD, Inc.
225 Varick Street, Suite 402
New York, New York 10014

Contact Us
Phone : 212-566-5555
Email : info@aatod.org

Social Sharing
RSS
Follow by Email
Facebook
Twitter
YouTube
LinkedIn
Instagram
Stay Connected to AATOD